GlassScriptPhysician profile
Hugo Lopez
NPI 1497193817
$10,204.57
in general payments reported to CMS, 2019-2025
37 companies · $610 in 2025
The $610 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,830 · 2022: $3,749 · 2023: $2,720 · 2024: $1,296 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,614.25 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,289.71 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,478.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $710.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $660.61 | 2021-2025 | Lifevest |
| Abbvie INC. | $655.25 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $532.19 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $528.52 | 2023-2025 | |
| Horizon Therapeutics Plc | $483.96 | 2021-2022 | |
| Janssen Biotech, INC. | $371.26 | 2022-2023 | Simponi Aria, Remicade, Simponi |
| Idorsia Pharmaceuticals US INC | $255.05 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $230.11 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.27 | 2021-2024 | Xifaxan, Trulance |
| Abiomed | $140.27 | 2023 | Impella |
| Si-Bone, INC. | $130.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $124.90 | 2022 | |
| Nevro Corp. | $121.77 | 2022-2023 | Senza |
| Dexcom, INC. | $116.71 | 2023 | Dexcom G7 Gss (161) |
| Corcept Therapeutics | $111.58 | 2022 | |
| Melinta Therapeutics, LLC | $107.45 | 2023 | Kimyrsa |
| Pfizer INC. | $102.25 | 2023-2024 | |
| Radius Health, INC. | $101.67 | 2021-2023 | Tymlos |
| Ucb, INC. | $99.23 | 2022 | |
| Mallinckrodt Hospital Products INC. | $91.39 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.57 | 2024-2025 | Trintellix |
| Arbor Pharmaceuticals, INC. | $55.19 | 2021 | |
| Aurinia Pharma U.S., INC. | $52.55 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.12 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $42.17 | 2022-2023 | Seglentis |
| Eisai INC. | $36.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.59 | 2021-2023 | Steglujan, Steglatro, Belsomra |
| Abbott Laboratories | $24.60 | 2022 | |
| Glaxosmithkline, LLC. | $22.53 | 2021 | |
| Antares Pharma, INC. | $20.46 | 2024 | Xyosted |
| Octapharma USA, INC. | $20.00 | 2022 | |
| Exact Sciences Corporation | $16.35 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $14.83 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.